This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama

Hepatitis A Vaccine Clinical Trial

Official title: Long Term Hepatitis A Virus (HAV) Antibody Persistence in Children Vaccinated With 1 Dose and Those Vaccinated With 2 Doses of Havrix in Panama

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the persistence of hepatitis A antibodies, approximately 8 years and 10 years post vaccination with the complete series of Havrix (2 doses) and the partial series completion (1 dose).

Clinical Trial Description

The study comprises of two independent cross-sectional surveys (Year 8 and Year 10). The first cross-sectional serosurvey will evaluate the long term persistence of immunity approximately 8 years post vaccine administration and the second cross-sectional study will evaluate long term persistence, approximately 10 years post vaccine administration. ;

Related Conditions & MeSH terms

• Hepatitis
• Hepatitis A
• Hepatitis A Vaccine

• NCT number: NCT02712359
• Study type: Interventional
• Source: GlaxoSmithKline
• Status: Completed
• Phase: N/A
• Start date: June 1, 2016
• Completion date: August 22, 2018